Dermata Therapeutics Cash Flow From Operations vs. Net Income
| DRMA Stock | USD 2.25 0.13 6.13% |
For Dermata Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Dermata Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Dermata Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Dermata Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Dermata Therapeutics over time as well as its relative position and ranking within its peers.
Check out Investing Opportunities. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dermata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Dermata Therapeutics Net Income vs. Cash Flow From Operations Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Dermata Therapeutics's current stock value. Our valuation model uses many indicators to compare Dermata Therapeutics value to that of its competitors to determine the firm's financial worth. Dermata Therapeutics is rated below average in cash flow from operations category among its peers. It is rated below average in net income category among its peers . At present, Dermata Therapeutics' Net Loss is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Dermata Therapeutics' earnings, one of the primary drivers of an investment's value.Dermata Net Income vs. Cash Flow From Operations
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Dermata Therapeutics |
| = | (11.16 M) |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Dermata Therapeutics |
| = | (12.29 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Dermata Net Income Comparison
Dermata Therapeutics is currently under evaluation in net income category among its peers.
Dermata Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Dermata Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Dermata Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Dermata Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Dermata Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 259.6 K | 272.6 K | |
| Operating Income | -11.3 M | -11.8 M | |
| Net Loss | -11.1 M | -11.6 M | |
| Income Before Tax | -11.1 M | -11.6 M | |
| Total Other Income Expense Net | 259.6 K | 272.6 K | |
| Net Loss | -8.6 M | -9.1 M | |
| Net Loss | -11.1 M | -11.6 M | |
| Income Tax Expense | -7.2 K | -6.9 K | |
| Interest Income | 259.6 K | 196.7 K | |
| Change To Netincome | 1.1 M | 944.1 K | |
| Net Loss | (72.28) | (75.89) | |
| Income Quality | 1.04 | 1.00 |
Dermata Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Dermata Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Dermata Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Dermata Therapeutics' important profitability drivers and their relationship over time.
Dermata Therapeutics Earnings Estimation Breakdown
The calculation of Dermata Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Dermata Therapeutics is estimated to be -2.0 with the future projection ranging from a low of -2.0 to a high of -2.0. Please be aware that this consensus of annual earnings estimates for Dermata Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-2 Lowest | Expected EPS | -2 Highest |
Dermata Therapeutics Earnings Projection Consensus
Suppose the current estimates of Dermata Therapeutics' value are higher than the current market price of the Dermata Therapeutics stock. In this case, investors may conclude that Dermata Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Dermata Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 1 | 65.49% | -1.65 | -2.0 | 15.24 |
Dermata Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Dermata Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Dermata Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Dermata Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Dermata Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Dermata Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Dermata Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Dermata Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Dermata Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-14 | 2025-09-30 | -0.32 | -1.65 | -1.33 | 415 | ||
2025-08-13 | 2025-06-30 | -0.44 | -2.67 | -2.23 | 506 | ||
2025-05-07 | 2025-03-31 | -0.45 | -1.2515 | -0.8015 | 178 | ||
2025-03-17 | 2024-12-31 | -0.32 | -0.92 | -0.6 | 187 | ||
2024-11-15 | 2024-09-30 | -26.4 | -20.4 | 6.0 | 22 | ||
2024-08-15 | 2024-06-30 | -3.79 | -4.18 | -0.39 | 10 | ||
2024-05-15 | 2024-03-31 | -5.4 | -7.05 | -1.65 | 30 | ||
2024-03-21 | 2023-12-31 | -0.78 | -0.21 | 0.57 | 73 | ||
2023-11-09 | 2023-09-30 | -0.63 | -0.54 | 0.09 | 14 | ||
2023-08-10 | 2023-06-30 | -0.92 | -0.63 | 0.29 | 31 | ||
2023-05-11 | 2023-03-31 | -2.65 | -2.27 | 0.38 | 14 | ||
2023-02-21 | 2022-12-31 | -3.2 | -2.4 | 0.8 | 25 | ||
2022-11-10 | 2022-09-30 | -3.52 | -3.2 | 0.32 | 9 | ||
2022-08-15 | 2022-06-30 | -5.12 | -3.84 | 1.28 | 25 | ||
2022-05-16 | 2022-03-31 | -6.4 | -5.28 | 1.12 | 17 | ||
2022-03-28 | 2021-12-31 | -5.68 | -4.16 | 1.52 | 26 | ||
2021-11-15 | 2021-09-30 | -7.36 | -13.76 | -6.4 | 86 | ||
2021-09-27 | 2021-06-30 | -22.56 | -11.2 | 11.36 | 50 | ||
2021-03-31 | 2020-12-31 | 0 | -1.2061 | -1.2061 | 0 | ||
2020-03-31 | 2019-12-31 | 0 | -0.7437 | -0.7437 | 0 |
Use Dermata Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dermata Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dermata Therapeutics will appreciate offsetting losses from the drop in the long position's value.Dermata Therapeutics Pair Trading
Dermata Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Dermata Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dermata Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dermata Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dermata Therapeutics to buy it.
The correlation of Dermata Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dermata Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dermata Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dermata Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Dermata Therapeutics position
In addition to having Dermata Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Industrials ETFs Thematic Idea Now
Industrials ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Industrials ETFs theme has 53 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Industrials ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
To fully project Dermata Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Dermata Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Dermata Therapeutics' income statement, its balance sheet, and the statement of cash flows.